Effects of Diterpenes Isolated from the Brazilian Marine Alga Dictyota menstrualis on HIV-1 Reverse Transcriptase

Abstract

It has been recently demonstrated that HIV-1 reverse transcriptase is the target of two diterpenes, (6R)-6-hydroxydichotoma-3,14-diene-1,17-dial (compound 1) and (6R)-6-acetoxydichotoma-3,14-diene-1,17-dial (compound 2), that inhibit HIV-1 replication in vitro. In this work, the effects of both diterpenes on the kinetic properties of the recombinant HIV-1 reverse transcriptase (RT) enzyme were evaluated. RNA-dependent DNA-polymerase (RDDP) activity assays demonstrated that both diterpenes behave as non-competitive inhibitors with respect to dTTP and uncompetitive inhibitors with respect to poly(rA)·oligo(dT) template primers. The K _i values obtained for compounds 1 and 2 were 10 and 35 μM, respectively. Neither of these diterpenes affected the DNA-dependent DNA-polymerase (DDDP) activity of the HIV-1 RT. The RDDP activities of AMV-RT and MMLV-RT enzymes were also inhibited by compounds 1 and 2. In contrast to the HIV-1 enzyme, the DDDP activities of AMV-RT and MMLV-RT enzymes were significantly reduced by compound 1. Taken together, our results demonstrate that compound 1 is a more effective inhibitor of the viral reverse transcriptases from HIV-1, AMV and MMLV than compound 2. The kinetic behavior analyses of the HIV-1 RT demonstrate that both diterpenes have similar mechanisms of inhibition of RDDP activity.

Abbreviations

Compound 1:(6R)-6-hydroxydichotoma-3,14-diene-1,17-dial

Compound 2:(6R)-6-acetoxydichotoma-3,14-diene-1,17-dial

HIV-1 RT:human immunodeficiency virus type-1 reversetranscriptase

AMV:avian myeloblastosis virus

MMLV:Moloney murine leukemia virus

Diterpenes - HIV-1 RT - AMV-RT - MMLV-RT - non-competitive inhibitors - uncompetitive inhibitors

References

• 1 Turner B G, Summers M F. Structural biology of HIV.  J Mol Biol. 1999;  285 1-32
• 2 Wang J, Smerdon S J, Jader J, Kohlstaedt L A, Rice P A, Friedman J M. et al . Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer.  Proc Natl Acad Sci USA. 1994;  91 7242-6
• 3 Parniak M A. HIV/AIDS after twenty-five years.  Int J Biochem Cell Biol. 2004;  36 1666-7
• 4 Sarafianos S G, Hughes S H, Arnold E. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs.  Int J Biochem Cell Biol. 2004;  36 1706-15
• 5 Nakashima H, Matsui T, Harada S, Kobayashi N, Matsuda A, Ueda T. et al . Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3′-azido-3′-deoxythymidine in vitro .  Antimicrob Agents Chemother. 1986;  30 933-7
• 6 De Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection.  Med Res Rev. 2000;  20 323-49
• 7 Teixeira V L, Cavalcanti D N, Pereira R C. Chemotaxonomic study of the diterpenes from the brown alga Dictyota menstrualis .  Biochem Syst Ecol. 2001;  29 313-6
• 8 Pereira H S, Leão-Ferreira L R, Moussatché N, Teixeira V L, Cavalcanti D N, Pereira R C. et al . Antiviral activity of diterpenes isolated from the Brazilian marine alga Dictyota menstrualis on human immunodeficiency virus type 1 (HIV-1).  Antiviral Res. 2004;  64 69-76
• 9 Hizi A, McGill C, Hughes S H. Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants.  Proc Natl Acad Sci USA. 1988;  85 1218-22
• 10 Fletcher R S, Holleschak G, Nagy E, Arion D, Borkow G, Gu Z WMA. et al . Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase.  Protein Expr Purif. 1996;  7 27-32
• 11 Huber H E, McCoy J M, Seehra J S, Richardson C G. Human immunodeficiency virus 1 reverse transcriptase, template binding, processivity, strand displacement synthesis and template switching.  J Biol Chem. 1989;  264 4669-78
• 12 Maga G, Ubiali D, Salvetti R, Pregnolato M, Spadari S. Selective interaction of the human immunodeficiency virus type I reverse transcriptase non-nucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.  Antimicrob Agents Chemother. 2000;  44 1186-94
• 13 Pauwels R, Andries K, Desmyter J, Schols D, Kukla M J, Breslin H J. et al . Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.  Nature. 1990;  343 470-4
• 14 Debyser Z, Pauwels R, Andries K, Desmyter J, Kukla M, Janssen P A. et al . An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives.  Proc Natl Acad Sci USA. 1991;  88 1451-5
• 15 Goldman M E, Nunberg J H, O"Brien J A, Quintero J C, Schleif W A, Freund K F. et al . Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity.  Proc Natl Acad Sci USA. 1991;  88 6863-7
• 16 Romero D L, Busso M, Tan C K, Reusser F, Palmer J R, Poppe S M. et al . Non-nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.  Proc Natl Acad Sci USA. 1991;  88 8806-10
• 17 Shaharabany M, Hizi A. The DNA-dependent and RNA-dependent DNA polymerase activities of the reverse transcriptases of human immunodeficiency viruses types 1 and 2.  AIDS Res Hum Retroviruses. 1991;  7 883-8
• 18 Ito M, Nakashima H, Baba M, Pauwels R, De Clercq E, Shigeta S. et al . Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)].  Antiviral Res. 1987;  7 127-37
• 19 Ninomya M, Matsuka S, Kawakubo A, Bito N. HIV-1 reverse transcriptase inhibitors containing hydroxydityodial ordictyodial.  Japan Kokai Tokkyo Koho. 1995;  285 877
• 20 Merluzzi V J, Hargrave K D, Labadia M, Grozinger K, Skoog M, Wu J C. et al . Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor.  Science. 1990;  250 1411-3